Please use this identifier to cite or link to this item:
Title: Impact of delay from transperineal biopsy to radical prostatectomy upon objective measures of cancer control.
Austin Authors: Qu, Liang G ;Jack, Gregory S ;Perera, Marlon ;Evans, Melanie;Evans, Sue;Bolton, Damien M ;Papa, Nathan
Affiliation: Urology..
Olivia Newton-John Cancer Wellness and Research Centre..
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne VIC, Australia..
Department of Surgery, University of Melbourne, Melbourne VIC, Australia..
Issue Date: Apr-2022
Date: 2021-09-06
Publication information: Asian journal of urology 2022; 9(2): 170-176
Abstract: Treatment delays in prostate cancer have been characterised, although not explicitly in men undergoing transperineal prostate biopsies. We aimed to determine if delays to radical prostatectomy correlate with adverse outcomes using a contemporary population-based cohort of men diagnosed by transperineal biopsies. This study analysed men with prostate cancer of the International Society for Urological Pathology grade group ≥2, diagnosed by transperineal prostate biopsies who underwent prostatectomy, using the prospectively data from 1 January 2014 to 30 June 2018 Prostate Cancer Outcomes Registry-Victoria. Data were analysed according to stratified demographic and disease characteristics. Time intervals from biopsy (28, 60, 90, 120, and 270 days) were compared using odds ratios and regression analyses for proportion of upgrading, early biochemical recurrence, pT3 disease at prostatectomy, and positive surgical margins. In total, 2008 men were analysed. There were 306 (16.7%) men with upgrading, 151 (8.4%) with biochemical recurrence, 1068 (54.1%) with pT3 disease, and 464 (23.1%) with positive surgical margins (percentages excluded patients with missing data). All adverse outcomes studied were significantly associated with higher prostate-specific antigen and grade at diagnosis. Delays of 120-270 days did not adversely alter the incidence of Gleason upgrading, pT3, or recurrence. Delays (most frequent 60-89 days, 28%) were associated with positive surgical margins but not monotonically. Regression modelling demonstrated no increased likelihood of most adverse outcomes for up to 270 days. Men with prostate cancer of grade group ≥2 diagnosed through transperineal biopsy may wait up to 270 days for a prostatectomy without a greater likelihood of upgrading, pT3 disease, positive surgical margins, or biochemical recurrence.
DOI: 10.1016/j.ajur.2021.08.008
ORCID: 0000-0002-5145-6783
Journal: Asian journal of urology
PubMed URL: 35509478
PubMed URL:
ISSN: 2214-3882
Type: Journal Article
Subjects: Biopsy
Disease progression
Prostate cancer
Treatment delay
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Sep 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.